PDZ-binding kinase as a prognostic biomarker for pancreatic cancer: a pan-cancer analysis and validation in pancreatic adenocarcinoma cells.
10.12122/j.issn.1673-4254.2025.10.17
- Author:
Jinguo WANG
1
;
Yang MA
2
;
Zhaoxin LI
3
;
Lifei HE
3
;
Yingze HUANG
4
;
Xiaoming FAN
5
Author Information
1. School of Public Health, Guilin Medical University, Guilin 541004, China.
2. School of Basic Medical Sciences, Guilin Medical University, Guilin 541004, China.
3. Department of Radiation Oncology, Affiliated Hospital of Guilin Medical University, Guilin 541001, China.
4. Affiliated Clinical Laboratory Center of Guilin Medical University, Guilin 541001, China.
5. Guangxi Key Laboratory of Tumor Immunity and Microenvironment Regulation, Guilin Medical University, Guilin 541004, China.
- Publication Type:Journal Article
- Keywords:
NCAPG2;
PDZ-binding kinase;
biomarker;
immune invasion;
pan-cancer analysis;
pancreatic cancer
- MeSH:
Humans;
Pancreatic Neoplasms/genetics*;
Prognosis;
Biomarkers, Tumor/genetics*;
Cell Line, Tumor;
Cell Proliferation;
Adenocarcinoma/metabolism*;
Tumor Microenvironment;
Cell Movement;
Mitogen-Activated Protein Kinase Kinases
- From:
Journal of Southern Medical University
2025;45(10):2210-2222
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVES:To investigate the prognostic significance of PDZ-binding kinase (PBK) in pan-cancer and its potential as a therapeutic target for pancreatic cancer.
METHODS:PBK expression levels were investigated in 33 cancer types based on data from TCGA, GEO and CPTAC databases. RT-PCR and Western blotting were employed to examine PBK expression in clinical pancreatic cancer specimens and cell lines. The diagnostic and prognostic value of PBK in pancreatic cancer was evaluated using survival analysis, Cox regression analysis, ROC curve analysis, and clinical correlation studies. Gene enrichment and immune correlation analyses were conducted to explore the potential role of PBK in tumor microenvironment, and its correlation with drug sensitivity was investigated using GDSC and CTRP datasets. In pancreatic cancer BXPC-3 cells, the effects of lentivirus-mediated PBK knockdown on cell proliferation, migration, and invasion were examined using CCK-8, colony formation, and Transwell assays. The interaction between PBK and non-SMC condensin II complex subunit G2 (NCAPG2) was analyzed using co-immunoprecipitation and Western blotting.
RESULTS:PBK was overexpressed in multiple cancer types, including pancreatic cancer. A high PBK expression was associated with a poor prognosis of the patients and correlated with immune infiltration and alterations in the tumor microenvironment. Elevated PBK expression was positively correlated with the sensitivity to MEK inhibitors (Trametinib) and EGFR inhibitors (Afatinib) but negatively with the sensitivity to Bcl-2 inhibitors (TW37) and niclosamide. In BXPC-3 cells, PBK knockdown significantly suppressed NCAPG2 expression and inhibited cell proliferation, migration, and invasion. Co-immunoprecipitation confirmed a direct binding between PBK and NCAPG2.
CONCLUSIONS:PBK is a key regulator of pancreatic cancer and interacts with NCAPG2 to promote tumor progression, suggesting its value as a potential biomarker and therapeutic target for pancreatic cancer.
